image
Healthcare - Medical - Diagnostics & Research - NYSE - US
$ 112.15
1.54 %
$ 13.5 B
Market Cap
48.76
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Mar, 2, 2025.

The intrinsic value of one RVTY stock under the worst case scenario is HIDDEN Compared to the current market price of 112 USD, Revvity, Inc. is HIDDEN

This DCF valuation model was last updated on Mar, 2, 2025.

The intrinsic value of one RVTY stock under the base case scenario is HIDDEN Compared to the current market price of 112 USD, Revvity, Inc. is HIDDEN

This DCF valuation model was last updated on Mar, 2, 2025.

The intrinsic value of one RVTY stock under the best case scenario is HIDDEN Compared to the current market price of 112 USD, Revvity, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS
FINANCIALS
2.76 B REVENUE
0.16%
347 M OPERATING INCOME
15.36%
270 M NET INCOME
50.63%
665 M OPERATING CASH FLOW
628.54%
-93.2 M INVESTING CASH FLOW
-7.10%
0 FINANCING CASH FLOW
100.00%
729 M REVENUE
6.63%
119 M OPERATING INCOME
20.99%
94.6 M NET INCOME
1.35%
174 M OPERATING CASH FLOW
17.81%
-17.3 M INVESTING CASH FLOW
-2.51%
-193 M FINANCING CASH FLOW
77.91%
Balance Sheet Revvity, Inc.
image
Current Assets 2.35 B
Cash & Short-Term Investments 1.16 B
Receivables 632 M
Other Current Assets 554 M
Non-Current Assets 10 B
Long-Term Investments 0
PP&E 650 M
Other Non-Current Assets 9.39 B
Current Liabilities 653 M
Accounts Payable 167 M
Short-Term Debt 242 K
Other Current Liabilities 485 M
Non-Current Liabilities 4.07 B
Long-Term Debt 3.3 B
Other Non-Current Liabilities 771 M
EFFICIENCY
Earnings Waterfall Revvity, Inc.
image
Revenue 2.76 B
Cost Of Revenue 1.22 B
Gross Profit 1.54 B
Operating Expenses 1.19 B
Operating Income 347 M
Other Expenses 76.4 M
Net Income 270 M
RATIOS
55.81% GROSS MARGIN
55.81%
12.59% OPERATING MARGIN
12.59%
9.81% NET MARGIN
9.81%
3.53% ROE
3.53%
2.18% ROA
2.18%
2.64% ROIC
2.64%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Revvity, Inc.
image
Net Income 270 M
Depreciation & Amortization 428 M
Capital Expenditures -86.6 M
Stock-Based Compensation 37.8 M
Change in Working Capital 0
Others 31.1 M
Free Cash Flow 578 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Revvity, Inc.
image
Wall Street analysts predict an average 1-year price target for RVTY of $128 , with forecasts ranging from a low of $110 to a high of $140 .
RVTY Lowest Price Target Wall Street Target
110 USD -1.92%
RVTY Average Price Target Wall Street Target
128 USD 14.58%
RVTY Highest Price Target Wall Street Target
140 USD 24.83%
4. DIVIDEND ANALYSIS
0.06% DIVIDEND YIELD
0.07 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership Revvity, Inc.
image
Sold
0-3 MONTHS
4.93 M USD 4
3-6 MONTHS
789 K USD 1
6-9 MONTHS
955 K USD 2
9-12 MONTHS
1.38 M USD 2
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
3 weeks ago
Feb 06, 2025
Sell 235 K USD
McMurry-Heath Michelle
Director
- 1970
119.49 USD
1 month ago
Jan 30, 2025
Sell 62.2 K USD
Goldberg Joel S
Please See Remarks
- 500
124.45 USD
1 month ago
Jan 30, 2025
Sell 341 K USD
Goldberg Joel S
Please See Remarks
- 2710
125.99 USD
1 month ago
Jan 30, 2025
Sell 1.35 M USD
Goldberg Joel S
Please See Remarks
- 10660
126.9 USD
1 month ago
Jan 30, 2025
Sell 166 K USD
Goldberg Joel S
Please See Remarks
- 1300
127.77 USD
1 month ago
Jan 07, 2025
Sell 282 K USD
Vohra Tajinder S
Please See Remarks
- 2430
116.13 USD
1 month ago
Jan 07, 2025
Sell 280 K USD
Vohra Tajinder S
Please See Remarks
- 2388
117.14 USD
1 month ago
Jan 07, 2025
Sell 55.8 K USD
Vohra Tajinder S
Please See Remarks
- 474
117.79 USD
1 month ago
Jan 07, 2025
Sell 23.8 K USD
Vohra Tajinder S
Please See Remarks
- 200
118.92 USD
3 months ago
Dec 02, 2024
Sell 1.75 M USD
Singh Prahlad R.
Please See Remarks
- 15088
116.13 USD
3 months ago
Dec 02, 2024
Sell 382 K USD
Singh Prahlad R.
Please See Remarks
- 3277
116.63 USD
4 months ago
Oct 09, 2024
Sell 260 K USD
Vohra Tajinder S
Please See Remarks
- 2134
121.72 USD
4 months ago
Oct 09, 2024
Sell 2.45 K USD
Vohra Tajinder S
Please See Remarks
- 20
122.56 USD
4 months ago
Oct 07, 2024
Sell 251 K USD
Vohra Tajinder S
Please See Remarks
- 2053
122.04 USD
4 months ago
Oct 07, 2024
Sell 12.3 K USD
Vohra Tajinder S
Please See Remarks
- 100
123.05 USD
4 months ago
Oct 08, 2024
Sell 203 K USD
Vohra Tajinder S
Please See Remarks
- 1661
122.47 USD
4 months ago
Oct 08, 2024
Sell 60.6 K USD
Vohra Tajinder S
Please See Remarks
- 493
122.99 USD
6 months ago
Aug 15, 2024
Sell 101 K USD
MICHAS ALEXIS P
Director
- 850
118.62 USD
6 months ago
Aug 07, 2024
Sell 112 K USD
Goldberg Joel S
Please See Remarks
- 964
116.06 USD
6 months ago
Aug 07, 2024
Sell 82.2 K USD
Goldberg Joel S
Please See Remarks
- 703
116.86 USD
6 months ago
Aug 07, 2024
Sell 93.3 K USD
Goldberg Joel S
Please See Remarks
- 785
118.8 USD
6 months ago
Aug 07, 2024
Sell 125 K USD
Goldberg Joel S
Please See Remarks
- 1048
119.48 USD
8 months ago
Jun 07, 2024
Sell 312 K USD
Goldberg Joel S
Please See Remarks
- 2824
110.32 USD
8 months ago
Jun 07, 2024
Sell 130 K USD
Goldberg Joel S
Please See Remarks
- 1176
110.8 USD
1 year ago
Feb 29, 2024
Sell 550 K USD
MICHAS ALEXIS P
Director
- 5000
109.98 USD
1 year ago
Feb 27, 2024
Sell 278 K USD
Vohra Tajinder S
Please See Remarks
- 2652
104.84 USD
1 year ago
Feb 27, 2024
Sell 556 K USD
Vohra Tajinder S
Please See Remarks
- 5266
105.66 USD
1 year ago
Feb 23, 2024
Sell 87.8 K USD
Goldberg Joel S
Please See Remarks
- 835
105.13 USD
1 year ago
Feb 23, 2024
Sell 120 K USD
Singh Prahlad R.
Please See Remarks
- 1144
105.13 USD
1 year ago
Feb 05, 2024
Sell 1.53 M USD
Singh Prahlad R.
Please See Remarks
- 14749
104.05 USD
1 year ago
Feb 05, 2024
Sell 678 K USD
Singh Prahlad R.
Please See Remarks
- 6468
104.8 USD
1 year ago
Feb 05, 2024
Sell 1.2 M USD
Goldberg Joel S
Please See Remarks
- 11546
104.08 USD
1 year ago
Feb 05, 2024
Sell 384 K USD
Goldberg Joel S
Please See Remarks
- 3662
104.8 USD
1 year ago
Feb 05, 2024
Sell 28.2 K USD
Goldberg Joel S
Please See Remarks
- 267
105.66 USD
7. News
Revvity Wins Permanent Injunction Enforcing Agreements with Cloud Software Group WALTHAM, Mass.--(BUSINESS WIRE)--Today, Revvity, Inc. (NYSE: RVTY) announced that the Massachusetts Superior Court has ruled in its favor and will issue a permanent injunction to enforce Revvity's rights under its agreements with Cloud Software Group (CSG) related to the Spotfire® software. This ruling follows a preliminary injunction issued in April 2024, which will become permanent, ensuring uninterrupted access to Spotfire software and support for Revvity and its customers, protecting operat. businesswire.com - 1 week ago
Revvity to Present at Upcoming Investor Conferences WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced it will present at the following investor conferences in March 2025: 46th Annual Raymond James Institutional Investor Conference Monday, March 3, 2025 7:30 a.m. ET - Max Krakowiak, senior vice president and chief financial officer TD Cowen 45th Annual Health Care Conference Tuesday, March 4, 2025 9:10 a.m. ET - Prahlad Singh, president and chief executive officer Leerink Partners Global Healthcare Conference Tuesday, M. businesswire.com - 1 week ago
Molecular Infectious Disease Testing Market to Hit USD 17.78 Billion by 2029 with 13.7% CAGR | MarketsandMarkets™. DELRAY BEACH, Fla., Feb. 13, 2025 /PRNewswire/ -- The global Molecular Infectious Disease Testing market, valued at US$8.49 billion in 2023, is forecasted to grow at a robust CAGR of 13.7%, reaching US$9.37 billion in 2024 and an impressive US$17.78 billion by 2029. Major drivers of market growth include rising burden of infectious diseases and rapid technological advancements in molecular diagnostics. The increased incidence of emerging infectious diseases and antibiotic-resistant infections leads to greater demand for accurate and reliable diagnostics. In addition, there are rapid advances in the efficiency of molecular testing techniques, such as PCR and next-generation sequencing, which have improved diagnostic capabilities. These provide results that are more sensitive and at a faster speed, and allow for the simultaneous identification of multiple pathogens, which becomes vital in handling complex and continually changing infectious disease threats. These are some of the major contributors to the growing market. Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=40667482 Browse in-depth TOC on "Molecular Infectious Disease Testing Market" 539 - Tables61 - Figures448 - Pages An advancement in multiplex testing which could transform the molecular infectious disease testing market, is the integrated, fully automated multiplex diagnostic platforms. It will combine testing for multiple pathogens in a single reaction with the advantage of full automation, right from sample preparation to result interpretation. The automation of multiplex testing minimizes the chance of human error, enhances throughput, and accelerates the diagnostic process. These are the factors why this technology will thrive in environments of high demand such as hospitals, urgent care centers, and public health labs. The more these systems become user-friendly and affordable, the greater their potential will be to enhance access to multiplex tests in more rapid and comprehensive infectious disease surveillance and management across a range of healthcare settings. Based on product & service, the global molecular infectious disease testing market has been segmented into reagents & kits, instruments, and services & software. The fastest-growing segment within the molecular infectious disease testing market is the reagents and kits, mainly due to their critical role in making it possible for an accurate and efficient diagnosis. The growing use of molecular testing in clinical practices has caused the demand for good quality reagents and kits since they are indispensable in PCR, next-generation sequencing, and other molecular assays. The expansion of testing volumes within diagnostic laboratories and hospitals further propels the growth. Moreover, increased accessibility to ready-to-use, standardized kits and reagents that enhance sensitivity and reduce the turnaround time accelerate their demand in the molecular infectious disease testing market. Categorized by type, the molecular infectious disease testing market is segmented into single plex testing and multiplex testing. The multiplex testing segment is expected to witness the highest growth rate in the molecular infectious disease testing market because of its ability to test for more than one pathogen in a single test. Such capability can considerably reduce the testing time and cost while improving efficiency and accuracy of diagnostics. This is very helpful in complex infections, which could be due to multiple pathogens. The increasing demand for this type of testing in healthcare settings having high patient numbers is further due to the need for comprehensive, timely diagnostic solutions. Technological advancements in multiplex assay platforms have made this testing become indispensable in improving the clinical outcome, enhancing infection control measures. Key players in the molecular infectious disease testing market include Danaher (US), F. Hoffmann- La Roche Ltd (Switzerland), bioMérieux (France), Hologic, Inc. (US), Abbott (US), Thermo Fisher Scientific Inc. (US), QIAGEN (Netherlands), Revvity (US), Siemens Healthineers AG (Germany), BD (US), Grifols, S.A. (Spain), DiaSorin S.p.A. (Italy), and Seegene Inc. (South Korea). These companies have a diversified product portfolio and a good geographic presence also. With growing global burden of infectious diseases and increasing need for accurate diagnostics, such players are well-positioned to develop novel diagnostic technologies and further expand their offerings. They expand their market share through subsidiaries across the world based on the strength of their R&D capabilities and diversified product and services portfolios. Their product launches, agreements, acquisitions, and partnerships further enhance their portfolio while expanding the reach of their global business. Request Sample Pages : https://www.marketsandmarkets.com/requestsampleNew.asp?id=40667482 The key players operating in this market are Danaher (US), F. Hoffmann-La Roche Ltd (Switzerland), bioMérieux (France), Hologic, Inc. (US), Abbott (US), Thermo Fisher Scientific Inc. (US), QIAGEN (Netherlands), Revvity (US), Siemens Healthineers AG (Germany), BD (US), Grifols, S.A. (Spain), DiaSorin S.p.A. (Italy), and Seegene Inc. (South Korea). The market players have adopted several strategies such as advanced product development, partnerships, expansions, and acquisitions to strengthen their market position. The organic and inorganic strategies have allowed the market players to expand across geographies through the provision of advanced molecular infectious disease tests. Danaher emerged as the leader in the molecular infectious disease testing market in 2023. Its position as the leader in the market across the US serves as a platform from where it can penetrate more into the developing economies and build its global presence across more geographies. The company is also responsible for innovation in its products to cater to the varied needs of customers worldwide. This has assisted the company in building on its leadership position in the market. Additionally, the company also adopts certain organic growth strategies by launching new products and seeking relevant regulatory clearances. For example, in March 2024, the US FDA cleared the Xpert Xpress GBS test. In November 2022, it launched the Xpert Xpress MVP, a multiplexed PCR test. Such strategic steps have helped the company stay continuously in the lead in the molecular infectious disease testing market. F. Hoffmann-La Roche Ltd is a significant global player in the molecular infectious disease testing market. Its broad portfolio and presence in all parts of the world have helped it sustain its competitive advantage. Roche has a very good direct and indirect distribution network around the world, which enables it to balance out demand fluctuations in the different markets. Its strategic emphasis on organic as well as inorganic growth strategies makes the company stronger in the marketplace. For example, in September 2024, Roche launched the cobas Respiratory flex test. This is the first test by Roche using Roche's innovative and proprietary TAGS (Temperature-Activated Generation of Signal) technology. This technology identifies as many as 15 pathogens in a single PCR test by using multiplex polymerase chain reaction testing combined with color, temperature, and data processing. All these strategies, coupled with its strong presence in the market, have given Roche further opportunities to enhance its position within the molecular infectious disease testing market. bioMérieux is a prominent player in the molecular infectious disease testing market. Its robust position in the market is due to extensive distribution networks in America, Europe, the Middle East & Africa, and Asia Pacific. High investment in research & development, coupled with organic growth strategies, also helps bioMérieux strengthen its position in the market. Such initiatives include the launching of products and gaining appropriate regulatory approvals in order to extend its market shares. In December 2024, bioMérieux announced that the company's BIOFIRE FILMARRAY Tropical Fever (TF) Panel has achieved USD FDA Special 510(k) clearance. This new, innovative PCR-based testing solution brings fast and accurate pathogen identification in patients suffering from unexplained fever to clinicians, optimizing the treatment overall. For more information, Inquire Now! Related Reports: Molecular Diagnostics Market Veterinary Diagnostics Market Molecular Quality Controls Market IVD Contract Manufacturing Market Genetic Testing Market Get access to the latest updates on Molecular Infectious Disease Testing Companies and Molecular Infectious Disease Testing Market Size About MarketsandMarkets™: MarketsandMarkets™ has been recognized as one of America's best management consulting firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients. Earlier this year, we made a formal transformation into one of America's best management consulting firms as per a survey conducted by Forbes. The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry. To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook. Contact:Mr. Rohan SalgarkarMarketsandMarkets™ INC.1615 South Congress Ave.Suite 103, Delray Beach, FL 33445USA: +1-888-600-6441Email: [email protected]Visit Our Website: https://www.marketsandmarkets.com/ Logo: https://mma.prnewswire.com/media/1868219/MarketsandMarkets_Logo.jpg https://www.prnewswire.com - 2 weeks ago
RVTY Q4 Earnings Beat Estimates, Sales Miss, Segments Robust Revvity's fourth-quarter results showcase strong growth in Diagnostics business, along with recovery in Life Sciences segmental sales. zacks.com - 1 month ago
Revvity (RVTY) Reports Q4 Earnings: What Key Metrics Have to Say While the top- and bottom-line numbers for Revvity (RVTY) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. zacks.com - 1 month ago
Revvity, Inc. (RVTY) Q4 2024 Earnings Call Transcript Revvity, Inc. (NYSE:RVTY ) Q4 2024 Earnings Conference Call January 31, 2025 8:00 AM ET Company Participants Steve Willoughby - Senior Vice President, Investor Relations Prahlad Singh - President & Chief Executive Officer Max Krakowiak - Senior Vice President & Chief Financial Officer Conference Call Participants Doug Schenkel - Wolfe Research Vijay Kumar - Evercore ISI Patrick Donnelly - Citi Michael Ryskin - Bank of America Puneet Souda - Leerink Partners Matt Sykes - Goldman Sachs Luke Sergott - Barclays Andrew Cooper - Raymond James Catherine Schulte - Baird Dan Brennan - TD Cowen Operator Hello, everyone, and welcome to Revvity's Fourth Quarter 2024 Earnings Call. My name is Lydia, and I will be your operator today. seekingalpha.com - 1 month ago
Revvity (RVTY) Surpasses Q4 Earnings Estimates Revvity (RVTY) came out with quarterly earnings of $1.42 per share, beating the Zacks Consensus Estimate of $1.36 per share. This compares to earnings of $1.25 per share a year ago. zacks.com - 1 month ago
Revvity forecasts 2025 revenue, profit below estimates amid weak biotech spending Medical equipment maker Revvity forecast full-year profit and revenue for 2025 below Wall Street estimates on Friday, as it expects soft demand for its products and services used in drug research. reuters.com - 1 month ago
Revvity Announces Financial Results for the Fourth Quarter and Full Year of 2024 WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) today reported financial results for the fourth quarter and full year ended December 29, 2024. Fourth Quarter 2024 The Company reported GAAP earnings per share of $0.78, as compared to $0.64 in the same period a year ago. GAAP revenue for the quarter was $729 million, as compared to $696 million in the same period a year ago. GAAP operating income from continuing operations for the quarter was $119 million, as compared to $77 million f. businesswire.com - 1 month ago
Revvity Gears Up for Q4 Earnings: What's in the Offing? RVTY's fourth-quarter results are likely to reflect decent performance in the Diagnostics segment. The Life Sciences segment is likely to have faced continued challenges in China. zacks.com - 1 month ago
Revvity (RVTY) Earnings Expected to Grow: Should You Buy? Revvity (RVTY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. zacks.com - 1 month ago
Will Revvity (RVTY) Beat Estimates Again in Its Next Earnings Report? Revvity (RVTY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report. zacks.com - 1 month ago
8. Profile Summary

Revvity, Inc. RVTY

image
COUNTRY US
INDUSTRY Medical - Diagnostics & Research
MARKET CAP $ 13.5 B
Dividend Yield 0.06%
Description Revvity, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment provides instruments, reagents, informatics, software, subscriptions, detection, and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as contract research and laboratory services. It also provides analytical technologies, solutions, and services for its customers to understand the characterize the health of various aspects, including air, water, and soil. In addition, this segment offers solutions to farmers and food producers; and analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries. The Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
Contact 940 Winter Street, Waltham, MA, 02451 https://www.perkinelmer.com
IPO Date July 6, 1965
Employees 11000
Officers Mr. Joel S. Goldberg Senior Vice President of Administration, General Counsel & Secretary Ms. Madhuri Hegde FACMG, Ph.D. Senior Vice President & Chief Scientific Officer Mr. Robert Francis Friel Advisor Ms. Miriame Victor Senior Vice President & Chief Commercial Officer Mr. Maxwell Krakowiak Senior Vice President & Chief Financial Officer Mr. Stephen Barr Willoughby Senior Vice President of Investor Relations & Head of ESG Ms. Magali Four Senior Vice President and Chief People & Culture Officer Mr. Tajinder S. Vohra Senior Vice President of Global Operations Dr. Prahlad R. Singh Ph.D. Chief Executive Officer, President & Director Mr. Bryan A. Kipp Senior Vice President of Technology & Licensing